Drug Substance Postapproval Changes Guidance: Determination of Impurity Profile Equivalence
52:19
Facility Readiness: GMPs, Quality Assessments, and Compliance Trends (15of16) GDF 2020
17:02
CDER BIMO: Electronic Submission Requirements for New Drug and Biologic Licensing Applications
5:01
Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic aci...
1:00:38
Sexually Transmitted Infections in Women – OWH Speaker Series
2:29:20
Navigating Controlled Correspondences to Support Generic Drug Development
0:24
Healthier Choices Made Easier: Proposed FDA Front-of-Package Nutrition Info Box
20:43
VIRTUAL PRESS CONFERENCE: FDA’s Proposed Rule on Reducing Nicotine Levels – 1/15/2025
1:04:05